A feasibility open-label clinical trial utilizing second-generation artificial intelligence based on the constrained-disorder principle in patients with Parkinson's disease

The results of this feasibility trial provide preliminary, hypothesis-generating evidence that CDP-based second-generation AI-driven personalized Levodopa dosing regimens may be technically feasible and potentially associated with clinical improvements in PD patients. However, the open-label design, small sample size, and absence of control conditions necessitate cautious interpretation. Adequately powered, randomized, double-masked controlled trials are needed to confirm these findings and rigorously evaluate efficacy and long-term effects.